FDA — authorised 8 November 2023
- Application: NDA217806
- Marketing authorisation holder: ELI LILLY AND CO
- Local brand name: ZEPBOUND
- Indication: SOLUTION — SUBCUTANEOUS
- Status: approved
🇺🇸 Zepbound in United States
FDA authorised Zepbound on 8 November 2023
Marketing authorisations
FDA
- Status: approved
Zepbound in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Other approved in United States
Frequently asked questions
Is Zepbound approved in United States?
Yes. FDA authorised it on 8 November 2023; FDA has authorised it.
Who is the marketing authorisation holder for Zepbound in United States?
ELI LILLY AND CO holds the US marketing authorisation.